Clinical trialNCT07154706RecruitingPhase 3Interventional

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

SponsorNuvation Bio Inc.Enrollment180Non-small Cell Lung Cancer (NSCLC)

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Princess Margaret Cancer Centre-University Health Network
Toronto, Ontario, Canada
Geoffrey Liu, MD
Recruiting
Mcgill University
Montreal, Quebec, Canada
Owen Scott, MD
Recruiting

China

Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Nan Wu, MD
Recruiting
Peking University People'S Hospital
Beijing, Beijing Municipality, China
Xiang Yan, MD
Recruiting
the First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Wenhua Liang, MD
Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Naiquan Mao, BS Clin Med
Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, Guangzhou, China
Haoxian Yang, MD
Recruiting
the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Xiangnan Li, MD
Recruiting
Tongji Hospital Tongji Medical College of Hust
Wuhan, Hubei, China
Qian Chu, MD
Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Yongsheng Wang, MD
Recruiting
Nantong Tumor Hospital
Nantong, Jiangsu, China
Xiaodong Zhang, BS Clin Med
Recruiting
the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jun Deng, MD
Recruiting
the First Affiliated Hospital of Xi'An Jiaotong University
Xi'an, Shaanxi, China
Yu Yao, MD
Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
Pingping Song, MD
Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China
Jianhua Shi, MS Clin Med
Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Caicun Zhou, MD
Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Peng Zhang, MD
Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Lijie Tan, MD
Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Qinghua Zhou, MD
Recruiting
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, China
Daqiang Sun, MD
Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Qixun Chen, BS Clin Med
Recruiting

United States

Ucla
Los Angeles, California, United States
Jonathan Goldman, MD
Recruiting
Uci Chao Family Comprehensive Cancer Center
Orange, California, United States
Zhaohui Arter, MD
Recruiting
Georgetown University Medical Cener (gumc)
Washington D.C., District of Columbia, United States
Stephen Liu, MD
Recruiting
Advent Health
Orlando, Florida, United States
Mark Socinski, MD
Recruiting
Saint Alphonsus Health System
Boise, Idaho, United States
Andrew Pierson, MD
Recruiting
Tulane Cancer Center
New Orleans, Louisiana, United States
Mark Sides, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Narjust Florez, MD
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Robert Shen, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Alexander Drilon, MD
Recruiting
Sarah Cannon Research Institute (scri) - Texas Oncology-Central South
Austin, Texas, United States
James Uyeki, MD
Recruiting
Md Anderson
Houston, Texas, United States
Yasir Elamin, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander Spira, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboTaletrectinib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Aug 2025
Primary completion: 30 Aug 2030
Completion: 30 Aug 2033
Last update posted: 19 May 2026
Registered enrollment: 180
Registry id: NCT07154706

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.